{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-036730","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2024-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.918277+00:00","generated_at":"2026-05-29T07:50:39.558567+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vaxart completes sentinel cohort enrollment in Phase 2b oral COVID vaccine trial","bullets":["Sentinel cohort of 400 participants randomized 1:1 to Vaxart's oral pill vaccine or approved mRNA comparator.","Last dose administered Nov 26, 2024; DSMB and FDA will review 30-day safety data before expanding.","Upon favorable review and BARDA approval, second part will enroll approximately 10,000 participants.","Project NextGen award (BARDA) valued at up to $456 million; trial includes >=25% over age 65.","Primary endpoint is relative efficacy vs mRNA comparator for prevention of symptomatic COVID-19 disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-036730","json":"https://secwatch.observer/filing/0001437749-24-036730.json","markdown":"https://secwatch.observer/filing/0001437749-24-036730.md","text":"https://secwatch.observer/filing/0001437749-24-036730.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774924036730/0001437749-24-036730-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774924036730/vxrt20241204_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T07:50:39.558567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}